This study indicates in patients with critical illness-associated hyperglycaemia that acute intravenous administration of GIP at pharmacological doses has no insulinotropic activity, does not reduce elevated blood glucose concentrations but does cause a significant postprandial rise in glucagon. This evidence concerns the gene GCG and Hyperglycemia.